In Oct 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, needs a much more notable warning of the opportunity chance of sudden hearing decline as the result of post-marketing and advertising reports of non permanent deafness connected to utilization of PDE5 inhibitors.[19][8] The FDA concluded that they had bee